Every 10-Q that SkyAI, Inc. (SKYA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SKYA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SKYA filings page.
SkyAI, Inc. reported unaudited results for the three and six months ended June 30, 2026. For the first half of 2026, the company recorded a net loss from continuing operations of $109,520,033, compared with income from continuing operations of $7,769,654 a year earlier, primarily reflecting losses on its Solana ("SOL") treasury holdings.
Staking revenue from SOL was $5,457,656 for the six-month period, but this was outweighed by an unrealized loss on digital commodities of $84,336,553 and a realized loss of $14,716,799. Legacy medical device net revenue was $192,780, with activity focused on sales and distribution after manufacturing was discontinued in 2025.
At June 30, 2026, SkyAI held 2,003,676 SOL with a cost basis of $381,570,910 and a fair value of $144,282,193, plus cash of $12,071,008. Total liabilities were $3,070,440 against stockholders’ equity of $157,280,135. Under its 2025 repurchase program, 1,213,669 shares had been bought back into treasury at a cost of $2,011,573.
Sharps Technology reported a sharp swing to loss in the quarter ended March 31, 2026 as its new digital commodity treasury strategy dominated results. Net revenue from medical devices was modest at $192,780, while staking revenue from Solana-based holdings contributed $3.1 million.
The company recorded an unrealized loss on digital commodities of $70.8 million and a realized loss of $10.8 million, driving a net loss of $86.2 million, or $1.19 per share, compared with net income a year earlier. Fair value of SOL holdings fell to $162.5 million from $250.1 million at December 31, 2025, despite maintaining over 2.0 million SOL tokens.
Cash increased to $12.3 million as SOL sales and staking inflows outweighed operating and financing outflows. The company repurchased 867,678 shares for about $1.6 million and ended the quarter with stockholders’ equity of $178.8 million against minimal liabilities. Segment reporting now separates medical devices from the digital commodity treasury, underscoring the strategic pivot toward Solana-based assets.
Sharps Technology (STSS) filed its Q3 2025 10‑Q, highlighting a major shift to a digital‑asset treasury anchored in Solana (SOL). As of September 30, total assets were $443.96M, including SOL at fair value of $404.20M and USDC of $14.70M. Cash was $10.52M. Management states current liquidity is sufficient for the next twelve months and no longer raises substantial doubt about going concern.
Operations reflected the pivot: product revenue was $83,622, and staking revenue was $2,205,423. The quarter included significant operating costs, including selling, general and administrative expenses of $110.72M and a $7.50M impairment of fixed assets tied to the exit from manufacturing, resulting in a net loss of $105.33M. A 10% change in SOL prices would have impacted income by about $40.4M for the period, underscoring market sensitivity.
Financing activity was robust, with $210.73M of net cash provided year‑to‑date. The company received $144.04M of digital assets and $86.10M of USDC from common stock issuances. Shares outstanding were 27,626,498 at quarter‑end and 28,226,153 as of November 14, 2025. Sharps now reports two segments: Medical Device Packaging Products and Digital Assets.